Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | BCHE | P06276 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | NPY1R | P25929 | 1/20 | 0.69 |
| ▸ | NPY2R | P49146 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PRKACA | P17612 | 2/20 | 0.67 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.67 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15225469 | 0.91 | KDM4E (0.75) | KDM4EBCHELMNAALOX15TSHR | |
| SCHEMBL12676576 | 0.87 | KDM4E (0.80) | KDM4EBCHETSHRPRKACARPS6KB1 | |
| SCHEMBL5521696 | 0.86 | KDM4E (0.75) | KDM4EBCHETSHRSMN1; SMN2 | |
| SCHEMBL1900960 | 0.86 | KDM4E (1.00) | KDM4EBCHELMNATSHRPRKACA | |
| SCHEMBL1899190 | 0.86 | KDM4E (0.82) | KDM4EBCHELMNATSHRTP53 | |
| SCHEMBL14364650 | 0.85 | KDM4E (0.77) | KDM4EBCHETSHRSMN1; SMN2PRKACA | |
| SCHEMBL14364657 | 0.85 | KDM4E (0.77) | KDM4EBCHETSHRSMN1; SMN2PRKACA | |
| SCHEMBL1900058 | 0.84 | KDM4E (0.71) | KDM4EBCHETSHRSMN1; SMN2 | |
| SCHEMBL1386316 | 0.83 | BCHE (0.68) | KDM4EBCHELMNAALOX15TSHR | |
| SCHEMBL28787605 | 0.83 | BCHE (0.84) | BCHETP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2322521-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | Vertex Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS, INCORPORATED | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | KDM4E 1132/4885BCHE 321/4885LMNA 4251/4885 |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | GSK3B, GSK3A, GSKIP | KDM4E 1132/4885BCHE 321/4885LMNA 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.